Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 1
Submit an article Journal homepage
150
Views
38
CrossRef citations to date
0
Altmetric
Research Article

Myeloablative Treatments for Multiple Myeloma: Update of a Comparative Study of Different Regimens Used in Patients from the Spanish Registry for Transplantation in Multiple Myeloma

Juan José Lahuerta Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Carlos Grande Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Joan Blade Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Joaquín Martínez-López Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Javier de la Serna Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Adrian Alegre Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
José García LaraÑa Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Dolores Caballero Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Javier de la Rubia Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Julián Marı´n Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Cristina Perez-Lopez Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Anna Sureda Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Antonio Escudero Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Rafael Cabrera Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Eulogio Conde Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Juan Carlos García-Ruiz Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Katty Pérez-Equiza Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Fernado Hernandez Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Luis Palomera Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Angel León Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Pilar Giraldo Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Carlos Solano Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
,
Joan Bargay Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
&
Jesús San Miguel Program for the Study and Treatment of Hematological Malignancies (PETHEMA) & Spanish Stem Cell Transplantation Group (GETH), Spanish Society of Hematology, Madrid, Spain
 show all
Pages 67-75 | Published online: 01 Jul 2009

  • Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. and Bataille, R. (1996) "A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma", N. Engl. J. Med. 335, 91-97.
  • Barlogie, B., Jagannath, S., Vesole, D.H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J. and Tricot, G. (1997) "Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma", Blood 89, 789-793.
  • Lenhoff, S., Hjorth, M., Holmberg, E., Turesson, I., Westin, J., Nielsen, J.L., Wisloff, F., Brinch, L., Carlson, K., Carisson, M., Dahl, I.M., Gimsing, P., Hippe, E., Johnsen, H., Lamvik, J., Lofvenberg, E., Nesthus, I. and Rodjer, S. (2000) "Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 year with newly diagnosed multiple myeloma: a population-based study Nordic. Myeloma Study Group", Blood 95, 7-11.
  • Blade, J., Esteve, J., Rives, S., Martinez, C., Rovira, M., Urbanolspizua, A., Marin, P., Carreras, E. and Montserrat, E. (2000) "Highdose therapy autotransplantation/intensification vs continued standard chmotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution". Bone Marrow Transplantation 26, 845-849.
  • Bjorkstrand, B.B., Ljungman, P., Svensson, H., Hermans, J., Alegre, A., Apperley, J., Blade, J., Carison, K., Cavo, M., Ferrant, A., Goldstone, A.H., de Laurenzi, A., Majolino, I., Marcus, R., Prentice, H.G., Remes, K., Samson, D., Sureda, A., Verdonck, L. F., Volin, L. and Gahrton, G. (1996) "Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation", Blood 88, 4711-4718.
  • Couban, S., Stewart, A.K., Loach, D., Panzarella, T. and Meharchand, J. (1997) "Autologous and allogeneic transplantation for multiple myeloma at a single centre", Bone Marrow Transplantation 19, 783-789.
  • McElwain, T.J. and Powles, R.L. (1983) "High-dose intravenous melphalan for plasma-cell leukaemia and myeloma", Lancet ii, 822-824.
  • Selby, P.J., McElwain, T.J., Nandi, A.C., Perren, TJ., Powles, R.L., Tillyer, C.R., Osbome, R.J., Slevin, M.L. and Malpas, J.S. (1987) "Multiple myeloma treated with high dose intravenous melphalan", Br. J. Haematol. 66, 55-62.
  • Sarosy, G., Leyland-Jones, B., Soochan, P. and Cheson, B.D. (1988) "The systemic administration of intravenous melphalan", J. Clin. Oncol. 6, 1768-1782.
  • Cunningham, D., Paz-Ares, L., Milan, S., Powles, R., Nicolson, M., Hickish, T., Selby, P., Treleavan, J., Viner, C. and Malpas, J. (1994) "High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma", J. Clin. Oncol. 12, 759-763.
  • Moreau, P., Kergueris, M.F., Milpied, N., Le Tortorec, S., Mahe, B., Bulabois, C., Rapp, M.J., Larousse, C., Bataille, R. and Harousseau, J.L. (1996) "A pilot study of 220mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity", Br. J. Haematol. 95, 527-530.
  • San Miguel, J.F., Bladé, J. and Garcia-Sanz, R. (1999) "Treatment of multiple myeloma", Haematologica 84, 36-58.
  • Mansi, J., da Costa, F., Viner, C., Judson, I., Gore, M. and Cunningham, D. (1992) "High-dose busulfan in patients with myeloma", J. Clin. Oncol. 10, 1569-1573.
  • Bensinger, W.I., Rowley, S.D., Demirer, T., Lilleby, K., Schiffman, K., Clift, R.A., Appelbaum, F.R., Fefer, A., Bamett, T., Storb, R., Chauncey, T., Maziarz, R.T., Klarnet, J., MeSweeney, P., Holmberg, L., Matoney, D.G., Weaver, C.H. and Buckner, C.D. (1996) "Highdose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma", J. Clin. Oncol. 14, 1447-1456.
  • Alegre, A., Lamana, M., Arranz, R., Fernandez-Villalta, M.J.,Tomas, J.F., Figuera, A., Camara, R., Steegman, J.L., Casado, F., Requena, M.J., Planas, J.L., Vazquez, L., Granda, A. and Fernandez-Rañada, J.M. (1995) "Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma", Br. J. Harmatol. 91, 380-396.
  • Alexanian, R., Dimopoulos, M., Smith, T., Delasalle, K., Barlogie, B. and Champlin, R. (1994) "Limited value of myeloablative therapy for late multiple myeloma", Blood 83, 512-516.
  • Ventura, G.J., Barlogie, B., Hester, J.P., Yau, J.C., LeMaistre, C.F., Wallersteitn, R.O., Spinolo, J.A., Dicke, K.A., Horwitz, L.H. and Alexanian, R. (1990) "High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma", Bone Marrow Transplantation 5, 265-268.
  • Fermand, J.P., Chevret, S., Ravaud, P., Divine, M., Leblond, V., Dreyfus, F., Mariette, X. and Brouet, J.C. (1993) "High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients", Blood 82, 2005-2009.
  • Adkins, D., Salzman, D., Boldt, D.H., Roodman, G.D., Kunh, J., Levine, S., Smith, L., Lyons, R., Freytes, C.O. and Le Maistre, C.F. (1992) "Phase I trial of dacarbacine with cyclophosphamide, etoposido, carmustine, and autologous bone marrow transplantation for advanced lymphoma and myeloma", Proc. Annu. Meet. Am. Soc. Clin. Oncal. 11, 1161, Abstract.
  • Long, G.D., Chao, N.J., Hu, W.W., Negrin, R.S., Wong, R.M., and Blume, K.G. (1996) "High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma", Cancer 78, 2502-2509.
  • Lahuerta, J.J., Martinez-Lopez, J., Grande, C., Blade, J., de la Sema, J., Alegre, A., Garcia-Lopez, J., Caballero, D., Sureda, A., de la Rubia, J., Alvarez, A.M., Marin, J., Escudero, A., Conde, E., Perez-Equiza, K., Garcia Ruiz, J.C., Moraleda, J.M., Leon, A., Bargay, J., Cabrera, R., Hemandez-Garcia, M.T., Diaz-Mediavilla, J. and San Miguel, J. (2000) "Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma", Br. J. Haematol. 109, 138-147.
  • Crilley, P., Topolsky, D., Bulova, S., Bigler, R. and Brodsky, I. (1990) "Bone marrow transplantation following busulfan and cyclophosphamide for acute myelogenous lekemia", Bone Marrow Transplantation 5, 187-191.
  • Gore, M.E., Selby, P.J., Viner, C., Claris, P.I., Meldrum, M., Miller, B., Bell, J., Maitland, J.A., Milan, S. and Judson, I.R. (1989) "Intensive treatment of multiple myeloma and criteria for complete remission", Lancet ii, 879-882.
  • Bataille, R. and Harousseau, J.L. (1997) "Multiple myeloma", N. Engl. J. Med. 336, 1657-1664.
  • Lokhorst, H.M., Sonneveld, P. and Verdonck, L.F. (1999) "Intensive treatment for multiple myeloma: where do we stand?", Br. J. Haematol. 106, 18-27.
  • Barlogie, B., Jagannath, S., Desikan, K.R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, A., Fassas, N., Singhal, S., Mehta, J., Anaissie, E., Dhodapkar, D., Naucke, S., Cromer, J., Sawyer, J., Epstein, J., Spoon, D., Ayers, D., Cheson, B. and Crowley, J. (1999) "Total therapy with tandem transplants for newly diagnosed multiple myeloma", Blood 93, 55-65.
  • Lemoli, R. M., Martinelli, G., Zamagni, E., Motta, M.R., Rizzi, S., Terragna, C., Rondelli, R., Ronconi, S., Curti, A., Bonifazi, F., Tura, S. and Cavo, M. (2000) "Engraftment, clinical, and molecular follow-up of patients with multiple myelon who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy", Blood 95, 2234-2239.
  • Patriarca, F., Damiani, D., Fanin, R., Grimaz, S., Geromin, A., Cemo, M., Sperotto, A., Silvestri, F., Zaja, F. and Baccarani, M. (2000) "High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome", Haematologica 85, 269-274.
  • Cunningham, D., Paz-Ares, L., Gore, M.E., Malpas, J., Hickish, T., Nicolson, M., Meldrum, M., Viner, C., Milan, S. and Selby, P.J. (1994) "High-dose melphalan for multiple myeloma: long-term follow-up data", J. Clin. Oncol. 12, 764-778.
  • Bariogie, B., Jagannath, S., Naucke, S., Mattox, S., Bracy, D., Crowley, J., Tricot, G. and Alexanian, R. (1978) "Long-term follow-up after high-dose therapy for high-risk multiple myeloma", Bone Marrow Transplantation 21, 1101-1107.
  • Bjorkstrand, B., Ljungman, P., Bird, J.M., Samson, D. and Gahrton, G. (1995) "Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma", Bone Marrow Transplantation 15, 367-371.
  • Bjorkstrand, B., Svensson, H., Ljungman, P., Apperley, J., Goldschmidt, H., Remes, P., Alegre, A., Marcus, R., Carlson, P., Coser, P., Sureda, A., Barbui, T., Goldstone, A.H., Bladè, J., Volin, L., Boogaerts, M., Lenhoff, S., Majolino, I., Samson, D., de-Laurenzi, A., Caballero, D. and Gahrton, G. (1997) "2522 autotransplants in multiple myeloma-a registry study from the European group for Blood and Marrow Transplantation (EBMT)", Blood 90(Suppl. 1), 419a.
  • Konigsberg, R., Zojer, N., Ackermann, J., Kromer, E., Kittler, H., Fritz, E., Kaufmann, H., Nosslinger, T., Riedl, L., Gisslinger, H., Jager, U., Simonitsch, I., Heinz, R., Ludwig, H., Huber, H. and Drach, J. (2000) "Predictive Role of Interphase Cytogenetics for Survival of Patients With Multiple Myeloma", J. Clin. Oncol. 18, 804-812.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.